WallStreetZenWallStreetZen

NASDAQ: INZY
Inozyme Pharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for INZY

Based on 6 analysts offering 12 month price targets for Inozyme Pharma Inc

Min Forecast
$11.00+937.74%
Avg Forecast
$17.83+1,582.36%
Max Forecast
$30.00+2,730.19%

Should I buy or sell INZY stock?

Based on 6 analysts offering ratings for Inozyme Pharma Inc.

Strong Buy
Strong Buy
3 analysts 50%
Buy
3 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although INZY's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates INZY as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their INZY stock forecasts and price targets.

INZY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-10
lockedlocked$00.00+00.00%2025-04-08
lockedlocked$00.00+00.00%2025-03-12
lockedlocked$00.00+00.00%2025-03-11
lockedlocked$00.00+00.00%2025-01-13
Wells Fargo
Bottom 4%
4
Strong BuyMaintains$11.00+937.74%2025-01-13

1 of 1

Forecast return on equity

Is INZY forecast to generate an efficient return?

Company
67.4%
Industry
146.26%
Market
80.85%
INZY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is INZY forecast to generate an efficient return on assets?

Company
31.64%
Industry
36.38%
INZY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

INZY earnings per share forecast

What is INZY's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$1.50
Avg 2 year Forecast
-$1.28
Avg 3 year Forecast
-$0.52

INZY revenue forecast

What is INZY's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$18.6M
Avg 2 year Forecast
$61.9M
Avg 3 year Forecast
$242.5M

INZY vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
INZY$1.06$17.83+1,582.36%Strong Buy
MAIA$2.30N/AN/A
ADAP$0.26$1.83+595.82%Buy
ADVM$3.23$22.67+601.76%Buy
WHWK$1.47N/AN/A
View Top Biotech Stocks

Inozyme Pharma Stock Forecast FAQ

Is Inozyme Pharma Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: INZY) stock is to Strong Buy INZY stock.

Out of 6 analysts, 3 (50%) are recommending INZY as a Strong Buy, 3 (50%) are recommending INZY as a Buy, 0 (0%) are recommending INZY as a Hold, 0 (0%) are recommending INZY as a Sell, and 0 (0%) are recommending INZY as a Strong Sell.

If you're new to stock investing, here's how to buy Inozyme Pharma stock.

What is INZY's earnings growth forecast for 2025-2027?

(NASDAQ: INZY) Inozyme Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.6%.

Inozyme Pharma's earnings in 2025 is -$102,024,000.On average, 7 Wall Street analysts forecast INZY's earnings for 2025 to be -$96,270,361, with the lowest INZY earnings forecast at -$122,056,376, and the highest INZY earnings forecast at -$73,876,228. On average, 7 Wall Street analysts forecast INZY's earnings for 2026 to be -$81,951,221, with the lowest INZY earnings forecast at -$101,499,513, and the highest INZY earnings forecast at -$64,882,600.

In 2027, INZY is forecast to generate -$33,404,903 in earnings, with the lowest earnings forecast at -$93,148,287 and the highest earnings forecast at $20,556,863.

What is INZY's revenue growth forecast for 2026-2028?

(NASDAQ: INZY) Inozyme Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.

Inozyme Pharma's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast INZY's revenue for 2026 to be $1,197,758,492, with the lowest INZY revenue forecast at $1,927,206, and the highest INZY revenue forecast at $2,393,589,777. On average, 5 Wall Street analysts forecast INZY's revenue for 2027 to be $3,974,541,050, with the lowest INZY revenue forecast at $878,163,507, and the highest INZY revenue forecast at $8,022,315,926.

In 2028, INZY is forecast to generate $15,580,175,221 in revenue, with the lowest revenue forecast at $4,952,276,864 and the highest revenue forecast at $26,285,804,218.

What is INZY's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: INZY) forecast ROA is 31.64%, which is lower than the forecast US Biotechnology industry average of 36.38%.

What is INZY's Price Target?

According to 6 Wall Street analysts that have issued a 1 year INZY price target, the average INZY price target is $17.83, with the highest INZY stock price forecast at $30.00 and the lowest INZY stock price forecast at $11.00.

On average, Wall Street analysts predict that Inozyme Pharma's share price could reach $17.83 by Apr 10, 2026. The average Inozyme Pharma stock price prediction forecasts a potential upside of 1,582.36% from the current INZY share price of $1.06.

What is INZY's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: INZY) Inozyme Pharma's current Earnings Per Share (EPS) is -$1.62. On average, analysts forecast that INZY's EPS will be -$1.50 for 2025, with the lowest EPS forecast at -$1.90, and the highest EPS forecast at -$1.15. On average, analysts forecast that INZY's EPS will be -$1.28 for 2026, with the lowest EPS forecast at -$1.58, and the highest EPS forecast at -$1.01. In 2027, INZY's EPS is forecast to hit -$0.52 (min: -$1.45, max: $0.32).

What is INZY's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: INZY) forecast ROE is 67.4%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.